New data related to GlaxoSmithKline’s CERVARIX(R) demonstrates that the cervical cancer candidate vaccine provides significant protection for women against the four most common cancer-causing human papillomavirus types. The vaccine gives protection for nearly six and a half years, which is the longest duration of protection reported to date. During this period, the vaccine showed 100% efficacy in preventing precancerous lesions due to cancer-causing virus types 16 and 18 as well as provided substantial protection against infection caused by virus types 31 and 45.